Director Jeffrey Sherman to retire from Xeris Biopharma board at 2026 annual meeting

Xeris Biopharma Holdings, Inc.

Dr. Jeffrey Sherman notified Board of his retirement and will not stand for reelection at the 2026 Annual Meeting.
Sherman will continue serving on Compensation and Nominating/Governance committees until his term expires.
Board reduced from eight to seven directors effective after Sherman's term ends at the 2026 Annual Meeting.
Sherman stated his retirement is not due to any disagreement with the company or its management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.